Citation 90620

ORI,K: KURODA,M: MIMAKI,Y: SAKAGAMI,H: SASHIDA,Y:. (2003). NORLANOSTANE AND LANOSTANE GLYCOSIDES FROM THE BULBS OF CHIONODOXA LUCILIAE AND THEIR CYTOTOXIC ACTIVITY.. 51(1)

Citation Details

TitleNORLANOSTANE AND LANOSTANE GLYCOSIDES FROM THE BULBS OF CHIONODOXA LUCILIAE AND THEIR CYTOTOXIC ACTIVITY.
AuthorsORI,K: KURODA,M: MIMAKI,Y: SAKAGAMI,H: SASHIDA,Y:
Year2003
Volume51
Issue1

Summary

Year: 2003

Journal: Unknown

Organisms and Their Experiments (1)

Chionodoxa luciliae (LILIACEAE)

Experiment #Pharmacology TypeWorktypesCompoundResults
1Not specified
VOUCHER SPECIMEN REPORTED FORISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
LANOST-8-EN-24-ONE,27-NOR: 3-BETA-[(O-BETA-D-APIOFURANOSYL(1-2)-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]-17-ALPHA-23-EPOXY-28-29-DIHYDROXY: 23(3):
None
2
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-24-ONE,27-NOR: 3-BETA-[(O-BETA-D-APIOFURANOSYL(1-2)-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]-17-ALPHA-23-EPOXY-28-29-DIHYDROXY: 23(3):
INACTIVE
3Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
LANOST-8-EN-23-ONE,27-NOR: 3-BETA-[(O-BETA-D-APIONFURANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]-17-ALPHA-24-EPOXY-28-29-DIHYDROXY: 23(S):
None
4
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-23-ONE,27-NOR: 3-BETA-[(O-BETA-D-APIONFURANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]-17-ALPHA-24-EPOXY-28-29-DIHYDROXY: 23(S):
INACTIVE
5Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
LANOST-8-EN-24-ONE,27-NOR: 17-ALPHA-23-EPOXY-28-29-DIHYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: 23(S):
None
6
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-24-ONE,27-NOR: 17-ALPHA-23-EPOXY-28-29-DIHYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: 23(S):
EQUIVOCAL
7Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
LANOST-8-EN-24-ONE,27-NOR: 17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: 23(S):
None
8
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-24-ONE,27-NOR: 17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: 23(S):
EQUIVOCAL
9Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
LANOST-8-EN-24-ONE,27-NOR: 17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[-BETA-D-GLUCOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: 23(S):
None
10
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-24-ONE,27-NOR: 17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[-BETA-D-GLUCOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: 23(S):
WEAK ACTIVITY
11Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
LANOST-8-EN-24-ONE,27-NOR: 17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[O-BETA-D-GLUCOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: 23(R):
None
12
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-24-ONE,27-NOR: 17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[O-BETA-D-GLUCOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: 23(R):
INACTIVE
13Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
LANOST-8-ENE-15-24-DIONE,27-NOR: 17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[O-BETA-D-GLUCOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]:
None
14
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-ENE-15-24-DIONE,27-NOR: 17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[O-BETA-D-GLUCOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]:
INACTIVE
15Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
LANOST-8-EN-23-26-OLIDE,3-BETA-[(O-BETA-D-APIOFURANOSYL(1-2)-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]-1-7-ALPHA-23-EPOXY-28-29-DIHYDROXY: (23S-25R):
None
16
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-23-26-OLIDE,3-BETA-[(O-BETA-D-APIOFURANOSYL(1-2)-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]-1-7-ALPHA-23-EPOXY-28-29-DIHYDROXY: (23S-25R):
INACTIVE
17Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
LANOST-8-EN-23-26-OLIDE,17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: (23S-25R):
None
18
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-23-26-OLIDE,17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: (23S-25R):
WEAK ACTIVITY
19Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
LANOST-8-EN-23-26-OLIDE,17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[O-BETA-D-GLUCOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: (23S-25R)
None
20
CYTOTOXIC ACTIVITY
PHARMACOLOGY OF COMPOUND - IN VITRO
LANOST-8-EN-23-26-OLIDE,17-ALPHA-23-EPOXY-29-HYDROXY-3-BETA-[(O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[O-BETA-D-GLUCOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL)-OXY]: (23S-25R)
WEAK ACTIVITY
Show SPARQL Queries (1)